Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q8N122
UPID:
RPTOR_HUMAN
Alternative names:
p150 target of rapamycin (TOR)-scaffold protein
Alternative UPACC:
Q8N122; B2RN36; C6KEF2; F5H7J5; Q8N4V9; Q8TB32; Q9P2P3
Background:
The Regulatory-associated protein of mTOR, also known as p150 target of rapamycin (TOR)-scaffold protein, is a pivotal component of the mTORC1 complex. This complex is a central nutrient sensor that stimulates anabolic reactions, promoting cellular growth by enhancing protein, lipid, and nucleotide synthesis. It achieves this by phosphorylating key substrates such as RPS6KB1 and EIF4EBP1. Concurrently, mTORC1 inhibits autophagy by phosphorylating ULK1, ATG13, and TFEB, thus regulating cellular catabolism.
Therapeutic significance:
Understanding the role of the Regulatory-associated protein of mTOR could open doors to potential therapeutic strategies.